From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?
{{output}}
Over the past two decades, precision oncology has seen unprecedented advances, particularly with the rise of small molecule drugs. These drugs have significantly benefitted patients with cancer harboring somatic genomic alterations, contributing to precision c... ...
